Molecular Templates is a biopharmaceutical company that focuses on developing targeted therapies for cancer treatment. Using their proprietary biologic engineered toxin body (ETB) drug platform, the company is creating novel therapeutic compounds that selectively target tumor cells. Their pipeline includes lead compounds for melanoma, with upcoming clinical trials, as well as additional compounds for various other cancers. Molecular Templates is also actively involved in collaborations, such as with Bristol Myers Squibb, to discover and develop new products. Founded in 2001 and headquartered in Austin, Texas, the company is making significant strides in the field of cancer therapeutics.